Viral Infections Respiratory Infections Policy & Practice Public Health Vaccines & Prevention

ACIP disruption leaves vaccine policy questions unresolved

Share

Objective:

To summarize unresolved vaccine policy questions amid ACIP disruption, the limits of professional-society guidance and panelists’ recommendations for evaluating and communicating vaccine information.

Approach:
  • : Panelists discussed vaccine advocacy and communication during an IDWeek 2026 session.
  • : Rochelle Walensky, MD, MPH, described ACIP’s evidence review, public deliberations and voting process, including how CDC adoption of recommendations influences immunization schedules, insurance coverage and the Vaccines for Children program.
  • : Speakers discussed professional-society recommendations, verification of guidance and communication with patients.
Key Findings:
  • Walensky said ACIP was unable to meet under a court order at the time of the session, with no policies moving forward, including policies concerning Vaccines for Children coverage.
  • Unaddressed issues included broadening measles vaccination, updating seasonal respiratory vaccine recommendations and addressing vaccine research gaps.
  • Research needs included RSV revaccination for adults older than 75, COVID-19 vaccination for health care personnel and an mRNA influenza vaccine for older adults.
  • Walensky stated that seasonal respiratory vaccine recommendations had not undergone CDC discussion since 2024.
  • Jason Goldman, MD, MACP, characterized professional-society guidance as a necessary temporary response that could not replace a fully staffed, vetted and appropriately constituted ACIP.
  • Demetre Daskalakis, MD, MPH, advised verifying CDC webpage updates through other sources. Walensky emphasized transparency in evidence-review methods, while Goldman recommended listening to patients’ concerns, explaining supporting data and encouraging scrutiny of information sources.
Interpretation:

The panelists described consequences extending beyond clinical recommendations because ACIP also has a federal role affecting vaccine coverage and access. Professional societies were providing guidance, but speakers emphasized the limits of that response.

Limitations:
  • The source reports conference presentations and discussion rather than an original research study.
  • Statements about ACIP’s ability to meet and the status of policy discussions reflect the circumstances described at the time of the session.
  • The article does not provide a complete review of the evidence underlying each vaccine policy or research question.
Conclusion:

IDSA called for restoring ACIP’s established vaccine recommendation process with qualified, appropriately vetted members. Panelists emphasized transparent evidence review, verification of information and patient conversations that explain supporting data and address individual concerns.

Sources: